Celiac disease affects roughly 1 in 70 people in parts of North India — a rate comparable to or exceeding prevalence in the U.S. and Europe — yet research from this region has been scarce. That may be shifting. Maharshi Dayanand University (MDU) in Rohtak, Haryana, has secured a Rs 25 lakh grant (approximately $30,000) for advanced celiac disease research, The Tribune reports. By Western pharmaceutical standards, $30,000 is a modest sum. But it signals something worth paying attention to: celiac research is expanding globally, and more scientific perspectives mean faster progress for patients and families everywhere.
What This Means for You
If you’re raising a child with celiac disease, you’re probably tracking research from the major centers — Boston, London, Stockholm, Melbourne. The science that ultimately helps celiac families, though, may increasingly come from places that don’t yet appear on your radar.
North India — particularly the states of Punjab, Haryana, and Uttar Pradesh — is sometimes called a “celiac belt.” The region carries some of the highest documented celiac prevalence in Asia, driven by a wheat-heavy diet and genetic patterns common across the population. Studies have identified rates as high as 1 in 96 in some North Indian cohorts, well within the range seen in the U.S. (roughly 1 in 133) and Europe (roughly 1 in 100). That represents tens of millions of people living with celiac disease or at risk of developing it — a massive patient population that remains underserved by current research.
Celiac disease also presents differently across populations. South Asian patients more often show the classic gastrointestinal symptoms — diarrhea, bloating, weight loss — while many Western adults present atypically with anemia, fatigue, or neurological symptoms and go undiagnosed for years. Research conducted in a North Indian population can reveal aspects of how the disease works that study cohorts in London or Chicago simply cannot replicate.
When MDU Rohtak investigates celiac disease with this funding, they’re studying it in a population with distinct genetic backgrounds, different wheat varieties, and different dietary patterns. That kind of diversity strengthens the global evidence base. A discovery from Haryana could validate a diagnostic biomarker identified in Europe — or challenge it, which is equally valuable.
As explored in our earlier piece on how federal research funding is advancing celiac disease science, investment in celiac research compounds over time. Findings from one lab inform trials in another country. Data from high-prevalence populations can fast-track understanding that took decades to accumulate through smaller Western cohorts alone.
Key Takeaways
- Celiac disease is as prevalent in parts of North India as in the U.S. and Europe, yet this region has been dramatically underrepresented in global research.
- Maharshi Dayanand University in Rohtak has secured Rs 25 lakh (approximately $30,000) for advanced celiac disease research — a meaningful step for South Asian celiac science.
- Research in diverse populations helps scientists understand the full range of how celiac disease presents, progresses, and responds to treatment.
- The grant is modest but functions as seed funding — the kind of preliminary work that attracts larger investment and generates publishable findings.
- Global expansion of celiac research accelerates progress for patients everywhere, regardless of where the lab is located.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
Why North India Has Elevated Celiac Rates
Celiac disease needs two conditions to develop: a genetic predisposition and repeated exposure to gluten (the protein complex in wheat, barley, and rye). North Indian populations have both.
On the genetic side, celiac is strongly linked to variants in the HLA (human leukocyte antigen) gene complex — the part of your DNA that governs how your immune system recognizes proteins. The variants HLA-DQ2 and HLA-DQ8 are present in over 95% of celiac patients worldwide. The most common celiac-associated marker, HLA-DQ2.5, is widespread across North Indian populations — explaining why prevalence in the region rivals rates in Europe, where the condition has been studied for decades.
On the dietary side, wheat has been a staple crop in Haryana and Punjab for millennia. These two states together supply a substantial share of India’s wheat. High lifelong gluten exposure in populations carrying HLA risk genes translates directly into elevated celiac rates.
What “Advanced Celiac Research” at This Stage Might Involve
MDU Rohtak’s specific research agenda was not detailed in initial reports, but university-level celiac work in this region typically addresses several high-value questions.
Wheat variety characterization is one productive direction. Not all wheat provokes the same immune response — a property researchers describe as differential immunogenicity (the degree to which a substance triggers the immune system). India cultivates both Triticum aestivum (common bread wheat) and Triticum durum (durum wheat, used for semolina and pasta), and these varieties carry distinct gluten protein profiles. Mapping which proteins in which varieties are most toxic to celiac patients could eventually guide crop development and inform food safety standards.
Biomarker research is another likely focus. A biomarker is a measurable biological signal — a protein in the blood, a pattern in tissue — that correlates reliably with disease activity. Current celiac diagnosis depends on blood tests measuring anti-tissue transglutaminase antibodies (anti-tTG), often confirmed by a small intestine biopsy. Researchers worldwide are working toward biomarkers that could diagnose celiac faster and less invasively. Validating whether biomarkers identified in European or American patients work equally well across South Asian genetic backgrounds is essential before any diagnostic tool can claim global applicability.
Epidemiological work — systematically mapping who has celiac disease, in what numbers, and under what conditions — fills a critical gap in India. The country still lacks a comprehensive national celiac prevalence dataset. Better data shapes clinical guidelines, medical training priorities, and government health policy. Without it, millions of patients go undiagnosed because their doctors aren’t looking.
Why Small Grants Matter in Academic Research
Rs 25 lakh (~$30,000) is not enough to fund a clinical trial. It is enough to fund preliminary experiments, generate publishable data, and build the case for a larger grant application. This is exactly how academic science works: seed funding produces findings, findings attract major institutional support, and major support produces the research that eventually reaches patients.
The Celiac Disease Foundation’s venture fund initiative operates on the same logic at a larger scale — strategic early investment in celiac research creates a compounding return as findings lead to more funding and, eventually, better tools for patients. University laboratories play a role that industry-funded research often cannot: investigating foundational science questions where the commercial return is too uncertain or too distant to attract private capital. Understanding why some people with the HLA-DQ2 gene develop celiac while others don’t, or how specific gluten peptides evade digestion and reach the immune system, is the kind of work that only academic labs will take on — and it’s the foundation on which treatments are built.
As a celiac parent, I track research news wherever it originates. My son lives with this disease every day. Anything that helps scientists understand it more completely — whatever country the lab happens to be in — is worth knowing about.
Related Coverage
- Celiac Disease Foundation Launches Venture Fund to Transform the Future of Celiac Disease
- How Federal Research Funding Is Advancing Celiac Disease Science
References
-
“Rohtak varsity secures Rs 25 lakh grant for advanced celiac disease research.” The Tribune, June 23, 2026. Source
-
Singh P, et al. “Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis.” Clinical Gastroenterology and Hepatology, 2018. doi:10.1016/j.cgh.2017.06.037
-
Makharia GK. “Understanding and managing celiac disease in clinical practice.” Journal of Gastroenterology and Hepatology, 2012.
-
Goel G, et al. “Spectrum of celiac disease in North India.” Indian Journal of Gastroenterology, 2019.
-
Sood A, et al. “Prevalence of celiac disease among school children in Punjab, North India.” Journal of Gastroenterology and Hepatology, 2006.